CrushSCI.com
169.9Average days
159Median days
66Fastest days
351Longest days
3382025 publications

Paper Review Records

All Paper Review Records

16 valid samples · Newest publication first
Review days = acceptance date − received date. PDF, DOI, and publisher-page sources are retained.

143 days

Atezolizumab–bevacizumab with or without cisplatin-based HAIC for unresectable HCC: A randomized phase II trial

Authors
Yasuto Takeuchi; Masahiko Sue; Nozomi Miyake; Takuya Adachi; Hideki Onishi; Miwa Kawanaka; Akinobu Takaki; Kazuhiro Nouso; Kazuya Kariyama; Tetsuya Yasunaka; Kenji Kuwaki; Junichi Toshimori; Shota Iwado; Akio Moriya; Hiroaki Hagihara; Hiroyuki Takabatake; Masahiro Sakata; Takeshi Hatanaka; Shigeo Shimose; Takumi Kawaguchi; Motoyuki OtsukaShow moreShow less
Affiliations
Department of Gastroenterology, Okayama University Hospital, Japan; Department of Gastroenterology, Okayama City Hospital, Japan; Department of Gastroenterology, Fukuyama City Hospital, Japan; Department of Gastroenterology, Okayama Saiseikai General Hospital, Japan; Department of Gastroenterology, Japanese Red Cross Okayama Hospital, Japan; Department of Gastroenterology, Hiroshima City Hospital, Japan; Department of Gastroenterology, Mitoyo General Hospital, Japan; Department of Gastroenterology, Sumitomo Besshi Hospital, Japan; Department of Gastroenterology, Kurashiki Central Hospital, Japan; Department of Gastroenterology, Fukuyama Medical Center, Japan; Department of Gastroenterology, Gunma Saiseikai Maebashi Hospital, Maebashi, Japan; Division of Gastroenterology, Department of Medicine, Kurume University School of Medicine, Kurume, JapanShow moreShow less
Source PDF DOI Publisher page
296 days

Integrative multi-omics identifies cholangiolocarcinoma as a distinct molecular subtype of intrahepatic cholangiocarcinoma

Authors
Jun Chen; Xuan Gao; Tianli Chen; Tianyi Dai; Aihua Yang; Xiangnan Xu; Jinhui Kong; Min Zhang; Guoliang Zhang; Ziyao Liu; Siyuan Liu; Yiqiang Chen; Xiaohong Pu; Biao Zhang; Jie Shen; Xinhua Zhu; Jingjing LiShow moreShow less
Affiliations
Department of Pathology, Nanjing Drum Tower Hospital Clinical College of Nanjing University of Chinese Medicine, Nanjing, 210008, Jiangsu, China; Department of Biobank, Nanjing Drum Tower Hospital Clinical College of Nanjing University of Chinese Medicine, Nanjing, 210008, Jiangsu, China; GenePlus-Shenzhen Clinical Laboratory, ShenZhen, 518122, Guangdong, China; Department of Precision Medical Center, Nanjing Normal University Nanjing Drum Tower Hospital, Nanjing, 210008, Jiangsu, China; The Precision Medicine Centre, Nanjing Drum Tower Hospital, Nanjing University Medical School, Nanjing, 210008, Jiangsu, China; Geneplus-Beijing, Beijing, 102205, China; Comprehensive Cancer Center, Department of Oncology, Nanjing Drum Tower Hospital Clinical College of Nanjing Medical University, Nanjing, 210008, Jiangsu, China; Division of Hepatobiliary and Transplantation Surgery, Department of General Surgery, Nanjing University Medical School Affiliated Nanjing Drum Tower Hospital, Nanjing, 210008, Jiangsu, China; Department of Laboratory Medicine, Nanjing Drum Tower Hospital, Clinical College of Nanjing Medical University, Nanjing, 210008, Jiangsu, ChinaShow moreShow less
Source PDF DOI Publisher page
164 days

Targeting circulating fatty acid-binding protein 4 ameliorates obesity-associated hepatic steatosis

Authors
Xingshan Jiang; Anthony Avellino; Jianyu Yu; Shanshan Liu; Longgang Zhao; Zhaohua Wang; Xiaochun Han; Himani Thakkar; Jonathan Shilyansky; Zhen Xu; Nicholas Schnicker; Bhagirath Chaurasia; Dustin E. Bosch; Jiaqing Hao; Xuehong Zhang; Sonia L. Sugg; Bing LiShow moreShow less
Affiliations
Department of Pathology, University of Iowa, Iowa City, IA, USA; Yale School of Nursing, Yale University, Orange, CT, USA; Department of Internal Medicine-Endocrinology and Metabolism, University of Iowa, Iowa City, IA, USA; Fraternal Order of Eagles Diabetes Research Center, University of Iowa, Iowa City, IA, USA; Protein and Crystallography Facility, University of Iowa, Iowa City, IA, USA; Holden Comprehensive Cancer Center, University of Iowa, Iowa City, IA, USA; Department of Surgery, University of Iowa, Iowa City, IA, USAShow moreShow less
Source PDF DOI Publisher page
154 days

EQ-5D health utility gains with once-weekly semaglutide 2.4 mg in people with MASH and F2/F3 fibrosis: An analysis of ESSENCE

Authors
Margarida Augusto; Robert Bauer; Simon Clancy; Aslak Sindbjerg Poulsen; Fotis Tefos; Michelle LongShow moreShow less
Affiliations
Novo Nordisk A/S, Søborg, Denmark; Novo Nordisk Ltd., Gatwick, United KingdomShow moreShow less
Source PDF DOI Publisher page
83 days

HBsAg isoforms predict HBsAg seroclearance and finite treatment in patients with chronic hepatitis B after cessation of long-term nucleos(t)ide analogs

Authors
Lung-Yi Mak; Mark Anderson; Rex Wan-Hin Hui; Tiffany Fortney; Karen Cheuk-Ying Ho; Rene Geissler; James Fung; Wai-Kay Seto; Gavin Cloherty; Man-Fung YuenShow moreShow less
Affiliations
Department of Medicine, School of Clinical Medicine, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong Special Administrative Region of China; State Key Laboratory of Liver Research, The University of Hong Kong, Hong Kong Special Administrative Region of China; Blizard Institute, Faculty of Medicine and Dentistry, Queen Mary University of London, UK; Abbott Laboratories, Abbott Diagnostics Division, Abbott Park, IL, USAShow moreShow less
Source PDF DOI Publisher page
176 days

Serum receptor-interacting protein kinase 3 (RIPK3) is associated with transplant-free survival in acute liver failure

Authors
Gautam Mehta; Chengyi Ding; Ugo Soffientini; Jaime L. Speiser; Sarah Bahnassi; Lily Dara; Valerie Durkalski; William M. Lee; Constantine J. KarvellasShow moreShow less
Affiliations
Institute for Liver and Digestive Health, University College London, London, UK; Roger Williams Institute of Hepatology, Foundation for Liver Research, London, UK; Department of Biostatistics and Data Science, Division of Public Health Sciences, Wake Forest University School of Medicine, Winston-Salem, NC, USA; Department of Medicine, University of Southern California, Los Angeles, CA, USA; Department of Public Health Sciences, Medical University of South Carolina, Charleston, SC, USA; Division of Digestive and Liver Diseases, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX, USA; Divisions of Hepatology and Critical Care Medicine, University of Alberta, Edmonton, CanadaShow moreShow less
Source PDF DOI Publisher page

FAQ

How long does JHEP Reports take to review a manuscript?

As of 2026-11-19, CrushSCI has 16 complete review records for JHEP Reports. The fastest paper went from submission to acceptance in 66 days (Corticosteroids in severe alcohol-related hepatitis: A multicenter randomized clinical trial, received 2026-05-05, accepted 2026-07-10); the slowest took 351 days. The average is 169.9 days and the median is 159 days.

Expert Matching · Case Demo

Turn Your Submission Goalsinto a Verifiable Journal Plan

Share your field, deadline, and author profile. CrushSCI uses real review records to suggest a title direction, shortlist journals, and estimate timelines.

We will reply within 30 minutes.

CrushSCI online

Client

I work in environmental engineering and need an SCI paper published within three months. I have no grant funding or prominent co-author. Which journals could I target?

CrushSCI

Yes. We will first screen for feasibility against the 90-day deadline, then identify comparable papers without grant support or prominent co-authors. The final shortlist will prioritize research quality and journal scope.

Suggested title
Machine Learning and Life-Cycle Assessment for Predicting and Optimizing Carbon Emissions in Urban Wastewater Treatment

SampleLatest 5 valid paper samples from 2026

Average review59.6 days

Median65 days

Contact CrushSCI

Contact CrushSCI

Leave your email address to discuss academic polishing, structural refinement, or one-to-one guidance.

We will reply within 30 minutes.

Selected service: Academic Consulting Service

Leave your email address

Or email us directly at leader@crushsci.com

Enter your email address so we can reply. Your details will remain private.